1.	Phase II Study of Recombinant Fowlpox Virus Encoding gp100 Peptide Preceded By an Endoplasmic Reticulum Insertion Signal in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0044, NCI-T98-0088, T99-0088, NCT00019669
2.	Phase II Randomized Study of Recombinant Fowlpox and Vaccinia Viruses Encoding Tyrosinase Antigen in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0095, NCI-T99-0025, T99-0025, NCT00019734
3.	Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Comprising Fludarabine and Cyclophosphamide Followed By Autologous Lymphocyte Infusion, Recombinant Fowlpox Virus Encoding gp100 Peptide, and Aldesleukin in Patients With Recurrent or Refractory Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-04-C-0152, NCI-6585, 6585, NCT00084500
4.	PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067036, E-7897, NCT00003871
5.	Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00) Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: NCI-95-C-0032D, NCI-T96-0026N, T96-0026
6.	Phase I Study of Immunization With a Recombinant Fowlpox Virus Encoding the gp100 Melanoma Antigen With or Without Concurrent Interleukin-2 in Patients With Recurrent Metastatic Melanoma (Summary Last Modified 04/2002) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0121, NCI-T94-0139N, T94-0139, NCT00019175